Vida Health, a virtual cardiometabolic care provider, is partnering with wearable device company ŌURA to integrate ŌURA’s biometric data into Vida’s clinical programs, the companies announced on Tuesday. Vida offers
Why Synthetic Data is the Antidote to Clinical Trials
Medical device innovation is laborious because of the high bar for validating that the technology does no harm. Patient recruitment for statistically powered trials stretches timelines and drives validation costs
Report: Growth in MA Is Associated With Lower Total Medicare Spending
Enrollment in Medicare Advantage has steadily increased over the past two decades. The number of MA enrollees grew from about 11 million (25% of total Medicare beneficiaries) in 2010 to
Hospital Margins Squeeze as Costs Outpace Revenue Growth
Hospitals’ financial positioning is somewhat stable but still under significant pressure, mainly from rising costs and reimbursement issues, according to data released last week by Kaufman Hall. The consulting firm
The AI Value Gap and Why Validation is a Practical First Win for Life Sciences
In life sciences, AI usually makes headlines for drug discovery, molecule design or clinical insights. Behind the scenes, though, the fastest and most repeatable wins are showing up in FDA-oriented
‘A Significant Assault on Our Health’: Healthcare Policy Leaders Condemn Trump’s Budget Proposal
To some, President Donald Trump’s budget proposal might be adding an insult to an injury. Last year, the federal government made significant cuts to healthcare coverage in Medicaid via the
Two New Takes on Making a Type of Targeted Cancer Therapy Even Better
Antibody drug conjugates bring a targeted approach to the treatment of many types of cancer, but there’s still room for improving this class of therapies. This week, two startups revealed
Inside The DOJ’s Hospital Contracting Crackdown: What Message Are the Feds Sending?
The Department of Justice is taking aim at two large health systems over contracts that the agency says stifle competition and keep patients from receiving affordable care. The lawsuits, both
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Many cancer drugs work by blocking proteins associated with tumor progression, but there’s growing industry interest in drugs that eliminate such proteins altogether. Gilead Sciences and Roche have both dipped
Healthcare’s Most Fixable Cost Problem: Administrative Waste
Over the years, we’ve seen certain kinds of healthcare costs steadily climb. Administrative expenses at urban hospitals, for example, rose more than 90% between 2011 and 2022, according to government









